F M Investments LLC Buys Shares of 4,129 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

F M Investments LLC bought a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 4,129 shares of the pharmaceutical company’s stock, valued at approximately $1,680,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. OFI Invest Asset Management acquired a new position in shares of Vertex Pharmaceuticals during the 3rd quarter valued at about $25,000. Arlington Trust Co LLC increased its stake in shares of Vertex Pharmaceuticals by 97.1% during the 4th quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 33 shares during the last quarter. Fortitude Family Office LLC acquired a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $30,000. Baystate Wealth Management LLC increased its stake in shares of Vertex Pharmaceuticals by 49.0% during the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after acquiring an additional 25 shares during the last quarter. Finally, NBC Securities Inc. acquired a new position in shares of Vertex Pharmaceuticals during the 3rd quarter valued at about $34,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX traded up $4.99 during trading hours on Tuesday, reaching $404.91. 1,070,081 shares of the company’s stock traded hands, compared to its average volume of 1,246,031. The firm has a market capitalization of $104.65 billion, a price-to-earnings ratio of 29.15, a P/E/G ratio of 1.86 and a beta of 0.35. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.99 and a quick ratio of 3.78. Vertex Pharmaceuticals Incorporated has a twelve month low of $316.43 and a twelve month high of $448.40. The business’s fifty day simple moving average is $413.00 and its two-hundred day simple moving average is $398.36.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, beating analysts’ consensus estimates of $3.85 by $0.35. The company had revenue of $2.52 billion for the quarter, compared to analyst estimates of $2.50 billion. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. During the same period last year, the company earned $3.33 earnings per share. Analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Amit Sachdev sold 3,222 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,354,013.28. Following the transaction, the executive vice president now owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Chairman Jeffrey M. Leiden sold 2,656 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $419.51, for a total value of $1,114,218.56. Following the transaction, the chairman now owns 27,644 shares of the company’s stock, valued at approximately $11,596,934.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Amit Sachdev sold 3,222 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,354,013.28. Following the transaction, the executive vice president now directly owns 74,364 shares in the company, valued at approximately $31,250,727.36. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,381 shares of company stock worth $5,203,249. 0.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on VRTX. Truist Financial increased their target price on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. StockNews.com downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $440.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 20th. JPMorgan Chase & Co. increased their price objective on shares of Vertex Pharmaceuticals from $390.00 to $438.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Finally, William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 6th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $429.45.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.